GlassScriptPhysician profile
Gerard Vockley
NPI 1912973447
$101,110.15
in general payments reported to CMS, 2019-2025
21 companies · $5,767 in 2025
The $5,767 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $22K · 2021: $11K · 2022: $6,075 · 2023: $3,155 · 2024: $32K · 2025: $5,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,625 · Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,365.18 |
| Travel and Lodging | $14,466.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,625.00 |
| Food and Beverage | $1,160.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $26,386.26 | 2019-2025 | Palynziq |
| Ptc Therapeutics, INC. | $19,775.74 | 2022-2025 | |
| Horizon Therapeutics Plc | $18,898.12 | 2019-2021 | |
| Sanofi US Services INC. | $9,300.00 | 2020 | |
| Agios Pharmaceuticals, INC. | $8,347.14 | 2019-2023 | |
| Amgen INC. | $5,703.00 | 2024 | Ravicti |
| Modernatx, INC. | $4,725.00 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $1,535.05 | 2024 | |
| Ipsen Innovation | $1,500.00 | 2024 | Iqirvo |
| Acadia Pharmaceuticals INC | $1,500.00 | 2025 | |
| Btg International INC. | $1,500.00 | 2023-2024 | |
| Tanabe Pharma America, INC. | $1,030.81 | 2025 | |
| Applied Therapeutics, INC. | $675.00 | 2021 | |
| Recordati_rare_diseases_inc. | $90.51 | 2024 | Cystadane, Panhematin, Carbaglu |
| Ultragenyx Pharmaceutical INC. | $69.50 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39.92 | 2022 | |
| Chiesi USA, INC. | $34.10 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Vockley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.